CD82 and breast cancer: Various clinical trial studies, involving cases of breast cancer diagnosed at varying stages, has shown that upregulated CD82 protein expression correlates with less malignant cases of diagnosed breast cancer, whereas down regulated CD82 protein expression shows correlation with highly malignant cases of diagnosed breast cancer (Al-Khater et al. 2021; Jee et al. 2006; Singh et al. 2016; Wang et al. 2019a, b).